Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (NASDAQ: FULC) enhances its leadership with the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Medical Officer and Jeff W. Jacobs, Ph.D., as Chief Scientific Officer. Dr. Arroyo, with nearly 20 years in biopharmaceuticals, previously led clinical developments at Momenta Pharmaceuticals. Dr. Jacobs brings over 25 years of drug discovery experience, most recently at Goldfinch Bio. Both executives aim to advance Fulcrum's clinical programs, including therapies for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease, by leveraging their extensive expertise.
Fulcrum Therapeutics (Nasdaq: FULC) announced its third-quarter 2022 financial results will be released on November 8, 2022, before U.S. markets open. Management plans to host a conference call at 8:00 a.m. ET to discuss the results and recent corporate developments. The company focuses on improving lives in genetically defined rare diseases and has ongoing clinical programs for losmapimod for FSHD and FTX-6058 for sickle cell disease. Interested parties can access the call through the Investor Relations section of the company's website.
Fulcrum Therapeutics (NASDAQ: FULC) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 2:35 p.m. PT, featuring a fireside chat. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 4:30 p.m. ET, also including a fireside chat. Interested investors can listen to live webcasts through the Investor Relations section of Fulcrum's website, with archived replays available for 30 days.
Fulcrum Therapeutics announced promising data from the open-label extension of its Phase 2 ReDUX4 trial of losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD). Findings suggest losmapimod modifies disease progression, with 97% of participants on treatment at 96 weeks demonstrating improved muscle function. The trial showcased a favorable safety profile, with no serious adverse events. The results will be presented at the World Muscle Society Congress on October 12, 2022, reinforcing the potential of losmapimod as a first approved treatment for FSHD.
Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of stock options for 6,180 shares to a new employee as inducement awards under its 2022 Inducement Stock Incentive Plan. The options, issued on October 3, 2022, have an exercise price of $8.16 per share, equal to the closing stock price on that date. These options will vest over four years, with a quarter vesting after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases with significant unmet medical needs.
Fulcrum Therapeutics (NASDAQ: FULC) announced the granting of 59,500 non-statutory stock options to three new employees on September 6, 2022. These options serve as inducement awards outside the 2019 Stock Incentive Plan. The exercise price is set at $7.47 per share, corresponding to the closing price on the grant date. Each option has a ten-year term with a four-year vesting period, allowing 25% to vest after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) is set to participate in key investor conferences, including the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference, which will feature a fireside chat on September 14, 2022, at 10:00 a.m. ET. The Morgan Stanley chat will be available live via the Fulcrum Investor Relations website, with a recording accessible for 30 days afterward. Fulcrum focuses on rare genetic diseases and has two lead programs in development: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced participation in a fireside chat at the Stifel 2022 Biotech Summer Summit on August 17, 2022, at 11:30 a.m. ET. The company focuses on developing treatments for genetically defined rare diseases, with lead programs including losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 targeting sickle cell disease. Fulcrum's proprietary platform, FulcrumSeek™, aims to address gene expression issues to tackle the root causes of these diseases. For more details, visit www.fulcrumtx.com.
Fulcrum Therapeutics (Nasdaq: FULC) announced a public offering of 9,590,792 shares of common stock at $7.82 per share, aiming to raise $75 million before expenses. The offering is led by Goldman Sachs and SVB Securities, with a 30-day option for underwriters to purchase an additional 1,438,618 shares. The closing date is projected for August 18, 2022. The shares are offered under an effective shelf registration statement with the SEC, ensuring compliance for the transaction. This move supports Fulcrum's focus on developing therapies for rare genetic diseases.
Fulcrum Therapeutics (Nasdaq: FULC) announced an underwritten public offering of $75 million in common stock, with an additional $11.3 million option for underwriters. Led by Goldman Sachs & Co. LLC and SVB Securities, the offering is subject to market conditions and may not guarantee completion. Shares will be offered under an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be available at SEC’s website. The funds will support Fulcrum’s clinical programs targeting rare diseases, including FSHD and sickle cell disease.